Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Increased by Rathbones Group PLC

Rathbones Group PLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 796,317 shares of the medical research company's stock after acquiring an additional 48,825 shares during the quarter. Thermo Fisher Scientific makes up 2.0% of Rathbones Group PLC's investment portfolio, making the stock its 9th largest position. Rathbones Group PLC owned approximately 0.21% of Thermo Fisher Scientific worth $414,268,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legacy Investment Solutions LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at $26,000. Barrett & Company Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $28,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 over the last quarter. Corporate insiders own 0.34% of the company's stock.

Remove Ads

Thermo Fisher Scientific Trading Up 2.4 %

NYSE:TMO traded up $10.47 during midday trading on Friday, reaching $437.91. 2,656,544 shares of the stock traded hands, compared to its average volume of 1,696,843. The stock has a market capitalization of $165.21 billion, a P/E ratio of 26.49, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a fifty day moving average of $510.56 and a 200 day moving average of $539.34.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.39%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research report on Friday, January 10th. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, Raymond James reiterated an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.